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Abstract We have isolated a novel gene which was expressed in 
normal rat cells, but completely suppressed in cells transformed 
b) v-src. The molecularly cloned cDNA was about 1.8 kb in size, 
containing an open reading frame composed of 464 amino acid 
residues. DNA sequence analysis showed that there was no 
corresponding ene in the data bases. Besides the suppression of 
gene expression in the v-src transformed cells, its expression was 
also strongly suppressed in cells transformed by other oncogenes 
such as v-abl, v-fps, v-mos, v-sis, v-K-ras, and polyomavirus 
middle T, but not affected in cells transformed by human 
papillomavirus type 16 E6E7 and polyomavirus large T. We 
named the gene drs for a gene _down-regulated by v-s_rc. 
~:,y words: drs gene; src gene; Transformation; Down- 
re gulation 
2. Materials and methods 
2.1. Cells 
No.7 cell line [17] is a hypoxanthine-guanine phosphoribosyl-trans- 
ferase (HGPRT) deficient strain of F2408 rat established cell line. 
SRD1 [18] is a No.7 cell line transformed by the SR-D strain of 
Rous sarcoma virus. No.7/HPVE6E7, No.7/PyMT and No.7/K-ras 
cells are No.7 cell lines transformed by human papillomavirus type 
16 (HPV16) E6E7, polyomavirus middle T (PyMT), and v-K-ras 
genes, respectively, as described previously [19]. No.7/fps, No.7/mos, 
No.7/sis and No.7/PyLT cells are No.7 cell lines transformed by v-fps, 
v-mos, v-sis, and polyomavirus large T (PyLT) genes, respectively. 
OS7-1 cell line [20] is a No.7 cell line containing a temperature-sensi- 
tive viral mutant of the v-src gene (OS122) [21,22]. The cell line shows 
transformed phenotypes at 35°C (permissive temperature) and 
changes to normal phenotypes at 39°C (non-permissive t mperature). 
All ceils were cultured in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 5% fetal bovine serum. 
1. Introduction 
The v-src oncogene, the transforming ene of Rous sarco- 
na  virus, encodes a protein kinase that phosphorylates tyro- 
s:ae residues of specific target proteins. Its normal counter- 
part, c-src, is thought to play an important role in 
ir, tracellular signal transduction which is related to cell pro- 
lii'eration [1] and differentiation [2,3], and the c-src kinase is 
tightly controled under normal conditions. However, the un- 
c,,ntrolled and activated protein-tyrosine kinase of v-src leads 
t~, cellular transformation [4]. Although v-src easily trans- 
f,,rms many rodent cell lines that have been established 
fiom fibroblasts, such as NIH3T3, 3Y1 and F2408, its trans- 
f,,rming ability is suppressed in primary rodent cells. In fact, it 
~as shown that primary rat embryo fibroblasts (REF) had 
il:tracellular functions capable of suppressing v-src-mediated 
tl ansformation [5]. 
Concerning alterations in gene expression upon transforma- 
tion by v-src, several cellular genes are induced, such as 9E3/ 
( EF4, c-jun, c-myc, c-fos and Egr-1, and some other genes are 
s',lppressed, such as fibronectin, MARCKS (a protein kinase- 
(substrate) ,  DAN and 322 [6-16]. Although the relationship 
bztween v-src-induced transcriptional changes of these genes 
aad the phenotypic alterations of transformed cells is unclear, 
d own-regulated genes should be more important as candidates 
f,w transformation suppressor genes. Indeed, DAN and 322 
gznes have been shown to be tumor-suppressor genes [14-16]. 
In this study, we report a gene whose expression is down- 
r,gulated by v-src. 
;:2orresponding author. Fax: (81) (6) 879-8315. 
**The nucleotide sequence data reported in this paper will appear in 
the DDBJ, EMBL and GenBank nucleotide sequence databases with 
the following accession umber D78359. 
2.2. Northern blot analysis 
Cellular RNA was isolated by a guanidium thiocyanate-CsC1 meth- 
od [23]. Total RNA (20 lag) was separated on a 1% agarose gel con- 
taining 2.2 M formamide and transferred to a nitrocellulose filter. The 
filter was hybridized with a probe labeled by a multiprime DNA 
labelling system (Amersham) at 41°C overnight in a solution of 50% 
formamide, 0.6 M NaCI, 60 mM sodium citrate, 0.2% sodium dodecyl 
sulfate (SDS), 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% poly- 
vinylpyrrolidone and 50 lag/ml of herring sperm DNA. The filter was 
washed with 15 mM NaCl, 1.5 mM sodium citrate, 0.1% SDS at 50°C 
and autoradiographed. 
2.3. Southern blot analysis 
Isolation of cellular high-molecular-weight DNA and DNA blot 
hybridization were performed as described previously [24,25]. DNA 
from each sample was digested with restriction enzymes, separated by 
1% agarose gel electrophoresis and transferred to a nylon filter. Hy- 
bridization and washing were performed as described for Northern 
blot analysis. 
2.4. Transfection and isolation of eDNA 
A cDNA expression library prepared with REF mRNA and the 
expression vector pAP3-neo was a gift from H. Nojima. SRD1 cells 
(5 x 10 ~) were transfected with 20 mg of the REF eDNA expression 
library by a calcium phosphate method modified by Chen and Okaya- 
ma [26]. After transfection, the cells were selected with a neomycin 
analogue G418 (400 mg/ml) for 2 weeks and morphologically flat 
clones were isolated from surviving colonies with cloning cylinders. 
From one of the flat clones, we rescued a plasmid containing an about 
1.0-kb eDNA insert by the Hirt method through cell fusion with 
COS7 cells as described by Okayama nd Berg [27]. The insert was 
used as a probe to isolate a full length of eDNA. Thus, a plasmid 
which had a eDNA insert about 1.8 kb was obtained. DNA was 
sequenced by a Li-Cor sequencer, model 4000 series, using a Se- 
quiTherm Cycle Sequencing Kit (Epicenter Technology). 
2.5. In vitro transcription-translation a alysis' 
Plasmid DNA (1.0 lag) was incubated with [zSS]methionine (transla- 
tion grade, Amersham) in a coupled transcription-translation assay 
system (TNT Kit, Promega). Products were analyzed by electrophor- 
esis in SDS/5-20% polyacrylamide gradient gels. Then the gels were 
fixed in methanol-acetic acid, immersed in Amplify (Amersham), dried 
and subjected to autoradiography. 
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Fig. 1. Expression and genomic structure of drs gene in No.7, SRD1 and OS7-1 cells. (a,c) Northern blot analysis. Total RNA (20 ~tg) was 
subjected to Northern blot analysis with a multiprime labeled rs cDNA (between -5 to 1300 nt, Fig. 2), GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), or ~-actin DNA. (b) Southern blot analysis. EcoRI-or PstI-digested genomic DNA (20 p.g) prepared from No.7 and SRD1 
were hybridized with the drs cDNA probe used for the above Northern blot analysis. 
3. Results 
3.1. Down-regulation o f  drs gene in v-src transformed cells 
To isolate a gene capable of suppressing v-src transforma- 
tion, we transfected a cDNA expression library prepared from 
REF mRNA into a v-src transformed cell line (SRD1), iso- 
lated several flat revertant clones and rescued plasmids carry- 
ing REF cDNAs from those revertant clones through cell 
fusion with COS7 cells. To examine whether expression of 
the genes corresponding to those cDNAs was affected by v- 
src transformation, wefirst performed Northern blot analyses 
of the corresponding genes in an untransformed cell line, 
No.7, and a v-src transformed cell line. For the analyses, 
each rescued cDNA was used as a probe. The results howed 
that expression of a gene hybridized with a 1.0-kb cDNA was 
almost completely suppressed in v-src transformed cells, as 
shown in Fig. la. An about 2.0-kb mRNA hybridizing with 
the cDNA was recognized in No.7 at a relatively high level, 
but almost completely disappeared in SRD1. REF and an- 
other rat cell line 3Y1 also showed a level of mRNA similar 
to No.7 cells (data not shown). Down-regulation of the 
mRNA was also observed in two other independently isolated 
No.7 cell lines transformed by v-src (data not shown). To 
verify that the disappearance of the mRNA was not due to 
rearrangement of the genomic DNA but was due to the reg- 
ulation of mRNA expression, Southern blot analysis of the 
genomic DNA prepared from No.7 and SRD1 cells was car- 
ried out. As shown in Fig. lb, the hybridization patterns of 
SRD1 DNA were identical to those of No.7 DNA. These 
results suggested that disappearance of the mRNA in SRD1 
cells was not due to loss or alteration of the genomic DNA. 
We also examined expression levels of the mRNA in a No.7 
cell line, OS7-1, containing a temperature-sensitive v-src mu- 
tant: the expression was similar to that in No.7 cells at 39°C 
(non-permissive temperature), whereas the expression was al- 
most completely suppressed at 35°C (permissive temperature) 
(Fig. lc). These results indicate that the down-regulation f 
the 2.0-kb mRNA is dependent on the expression of the v-src 
oncogene. 
3.2. drs gene encoded a transmembrane protein which had three 
consensus repeats o f  the selectin family 
To isolate a full length of cDNA, screening of the REF 
cDNA library was performed with a probe of the 1.0-kb 
cDNA insert. We obtained positive clones with about 1.8-kb 
cDNA inserts. The longest cDNA we obtained consisted of 
1830 base pairs (Fig. 2a), supposedly covering almost the 
entire 2.0-kb mRNA because an average size of polyadenyla- 
tion sequences i usually 2-300 bases. The cDNA had one 
long open reading frame (ORF) which extended from nucleo- 
tide position 66 to 1522, encoding 464 amino acids. Although 
no termination codon in frame was found in the 5' region 
upstream of the presumed initiation codon, the sequence 
around the initiation codon (CTCGCCATGG) was consistent 
with Kozak's consensus sequence (GCCA/GATGG) [28]. The 
molecular weight of the protein which encoded 464 amino 
acids was estimated to be 51.6 kDa. This was consistent 
with the result obtained from an in vitro transcription-trans- 
lation experiment, by which an about 52 kDa product was 
identified (Fig. 3). Although homology search was performed 
at the nucleotide l vel by both BLAST and FASTA programs 
through the Genbank data base, no corresponding gene was 
found, suggesting that this gene was a novel one. We named 
this gene drs for a gene down-regulated by v-src. Further 
homology search of drs protein revealed that the protein 
had one transmembrane domain (TM) (amino acid residues 
376-413) and three consensus repeats (CR) (amino acid resi- 
dues 57-115, 120-174 and 262-317) which were conserved as 
various numbers of CR in the extracellular domain of the 
selectin family, such as P-selectin, E-selectin and L-selectin. 
Based on these results, it is likely that the drs gene encodes 
a transmembrane protein with the three CR in the extracel- 
lular domain. 
To examine the genetical conservation of the drs gene, 
we carried out Southern blot analyses of genomic DNA ob- 
tained from mouse, monkey and human. As shown in Fig. 4, 
hybridized bands were recognized in all samples, suggesting 
that the drs gene was conserved in the various mammalian 
cells. 
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1711 C CTT~T~TC Tr ATTGTr TATATAAGTCTI'TI'GTTAATAMATATT]'TGAAGC AAA 
b 
CRI of drs(57-115) PIKVKY* DVY PP GYYKTALGTR YE H SS SNRR KVI ° QKR 
CR2 of drs(120-174) [~PT[qT~ANNGFK[~VD**HAYFN*B***R~yy~pI(~YTII~KI(~ERTVT]~WDNKA~SGRPAS[II~VDME 
CR3 of drs(262-317) BGKILINAL~ENL~Y~K~SD*~DN*[~GA***T~E[~S~I[IGL~yEHQL~sPAR~SNLA~SGTE~]S~WN 
} ig. 2. (a) The nucleotide sequence of drs eDNA and its deduced amino acid sequence. The nucleotides and amino acids are numbered from 
lie beginning of translation initiation. Double underlines indicate consensus repeat domains and a wavy line shows a transmernbrane domain. 
A stop eodon is shown by an asterisk. A polyadenylylation signal is underlined. (b) Comparison of the CR amino acid sequences of Drs pro- 
l~:in with a consensus sequence of P-selectin CR (GMP-140). The top is the consensus sequence of CR in P-selectin (GMP-140) [29]. Below 
iris, the three CR sequences of Drs are shown. The boxed residues how conserved residues in at least five out of the nine repeats in GMP- 
40. The shaded areas show the position of conserved cysteine residues. Asterisks how deletion of the corresponding amino acid residues. 
.3 .  drs gene expression was also down-regulated in cell lines 
transformed by other oncogenes 
To examine whether the suppression of drs gene expression 
was specific to v-src or general to cell transformation, we 
~,malyzed the drs mRNA expression i  various cell lines trans- 
Jormed by other oncogenes using Northern blot hybridization. 
• \s  shown in Fig. 5, in the cell lines transformed by v-abl, v- 
Ins, v-mos, v-sis, PyMT or v-K-ras, its expression was extre- 
mely down-regulated. In contrast, it did not change in cell 
lines transformed by HPV16 E6E7 or PyLT. These results 
indicated that down-regulation of drs gene was not a general 
event for cell transformation, and suggested that the down- 
regulation may have been related to some specific signal trans- 
duction pathways. 
4. Discussion 
We have isolated a novel gene, drs, whose mRNA expres- 
sion was down-regulated by v-src or some other oncogenes. 
The cDNA consisted of 1830 nucleotides and encoded an 
open reading frame of 464-amino-acid protein. Although no 
highly homologous genes were found by homology search, the 
24 J. Pan et al./FEBS Letters 383 (1996) 21-25 
i ,  
KD 
200 
97,4  m 
66.0 -  
46.0 -  
30.0 -  
21.5 -  
14.3 - 
Fig. 3. In vitro transcription-translation of drs eDNA. Coupled 
transcription-translation assay was performed with 1 mg of drs 
eDNA or vector as described in section 2. 
drs gene contained three CR sequences identified in the selec- 
tin family (Fig. 2b). 
The selectins are carbohydrate-binding adhesion molecules 
that regulate leukocyte ntry into lymphoid tissues or sites of 
inflammation [30,31]. This family includes E-, P-and L-selec- 
tins, and all of them consist of five structurally different do- 
mains, i.e. an amino-terminal lectin (Leu) domain, an epider- 
mal growth factor (EGF)-like domain, 2 to 9 CR sequences, a 
transmembrane domain, and a short cytoplasmic arboxyl- 
terminal domain [29,32-35]. Although there is shared se- 
quence homology among those three members of the selectin 
family, they differ in the number of CR repeats. L-, E-and P- 
selectins have two, six and nine CR repeats, respectively. Mu- 
tational analyses have demonstrated the crucial roles of the 
lectin and EGF-like domains in selectin-mediated a hesion 
[36]. Although the role of CR in selectin is not yet well de- 
fined, there are some reports that suggested involvement of 
CR repeats in adhesion function of both L-and E-selectins 
[37,38]. However, because drs protein has no Leu and EGF- 
like domains, it is unclear whether this protein acts as an 
adhesion molecule like selectin. 
Expression of the drs gene is strongly suppressed in the cell 
lines transformed by not only v-src gene but also other onco- 
genes such as v-abl, v-fps, v-mos, v-sis, v-K-ras and PyMT. 
However, its expression was not altered in the cell lines trans- 
formed by HPV16 E6E7 or PyLT. As well as the v-src gene 
product, the products of v-abl and v-fps genes have protein- 
tyrosine kinase activity, and PyMT is a constitutive activator 
of pp60 .. . . .  tyrosine kinase activity [3941]. v-sis encodes B 
chain of PDGF [42], binds to PDGF receptor, and activates 
tyrosine kinase of the receptor. The ras product is known to 
mediate the signals from those tyrosine kinases to serine- 
threonine kinases like raf kinase. The mos gene product is a 
member of the serine-threonine kinases [43] and suspected to 
have a similar function to rafkinase. Further, the products of 
v-abl, v-src, v-fps, v-ras and v-mos, and PyMT are known to 
activate MAP kinase through raf-1 [44,45]. Some of these 
oncogenes can also activate the PI3 kinase or the protein 
kinase C dependent pathways [46,47]. Therefore, all of these 
oncogenes may promote cell growth by activating mitogenic 
signal transduction pathways. On the other hand, the mechan- 
ism of growth promotion by HPV16 E6E7 and PyLT may be 
quite different. These oncogenes are thought o promote cell 
cycle by binding to and inactivating p53 or the pRB tumor 
suppressor gene product, either of which negatively regulates 
cell cycle [48,49]. These suggest hat down-regulation may be 
the event that is directly or indirectly related to specific signal 
transduction pathways rather than a general phenomenon of 
transformation. Some transcriptional factor downstream of 
the signal transduction pathway(s) may regulate the expres- 
sion of the drs gene. 
As drs gene expression is down-regulated in cell lines trans- 
formed by various oncogenes, the gene may function inhibit- 
ingly to cell transformation. Therefore, it is interesting to ex- 
amine whether expression of drs gene could result in 
suppression of cell transformation. In a preliminary experi- 
ment, we transfected SRD1 cells with drs expression vector, 
but could not detect obvious transformation suppressor activ- 
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Fig. 4. Detection of drs gene in various mammalian species. PstI-di- 
gested genomic DNAs (20 lig) derived from the human, monkey, 
mouse and rat were hybridized with the same drs eDNA probe used 
in Fig. la. 
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F g. 5. Expression of drs mRNA in cell lines transformed by various 
or~cogenes. Total RNA (20 p,g) from the cell lines transformed by 
e~ch oncogene was subjected to agarose gel electrophoresis, trans- 
fer'red to a nitrocellulose membrane, and hybridized with labeled rs 
p~obes used in Fig. la. 
il,l thus far. Further studies are necessary to reach a final 
c, mclusion on this matter. 
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